Mitchel Berger, M.D.
	Gliomas and nanoliposomes
	Email: bergerm@neurosurg.ucsf.edu Websites:
Selected Publications | Complete Publications

My research and its relevance to stem cell research is multifaceted. I am involved with the Molecular Marker Core in our department in terms of correlative biology and outcome of patients with both low-grade and high-grade gliomas. I am also involved in the Molecular Imaging Program, in which we correlate tissue samples with imaging-based biopsies to develop a panel of surrogate imaging markers for various biological processes that result in tumor growth, angiogenesis, etc. The other aspect of my research involves drug delivery, and to this end I have been part of the team that is developing nanoliposomes for treatment of malignant brain tumors. We have already developed a CPT-11 construct that we ve tested in canine models, using convection-enhanced delivery, and have been given FDA approval to bring this back for a clinical trial in brain tumors. Also, my research has involved DNA damage and repair mechanisms in gliomas, especially as it relates to alkyltransferase levels and promotor methylation of the MGMT gene in response to alkylating agents such as temozolomide.

Selected Publications

Berger MS. Intraoperative MR imaging: making an impact on outcomes for patients with brain tumors. AJNR 22(1):2, 2001.

Ware ML, Binder DK, Berger MS. Molecular biology of glioma tumorigenesis. Histol Histopathol 18(1):207-16, 2003.

Gupta N, Berger MS. Brain mapping for hemispheric tumors in children. Pedia Neurosurg, 2003 Jun;38(6):302-6.

ChaS, Lupo JM, Chen MH, Lamborn KR, McDermott MW, Berger MS. Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol. 2007 Jun-Jul:28(6):1078-84.

Information last updated September 2007